Colorectal cancer screening programs: how should we improve efficacy?

Endoscopy
DOI: 10.1055/a-2563-0251

Editorial

Referring to Larsen PT et al. doi: 10.1055/a-2551-1471

Marek Bugajski

¹Department of Gastroenterology, Luxmed Oncological Hospital, Warsaw, Poland

²Faculty of Medicine, Łazarski University, Warsaw, Poland

References
1 Larsen PT, Jørgensen SF, Rasmussen M. et al. Colorectal cancer incidence following a negative colonoscopy in fecal immunochemical test-based screening: a nationwide cohort study after 8 years of screening in Denmark. Endoscopy 2025; 57
2 Pilonis ND, Bugajski M, Wieszczy P. et al. long-term colorectal cancer incidence and mortality after a single negative screening colonoscopy. Ann Intern Med 2020; 173: 81-91
3 Bretthauer M, Løberg M, Wieszczy P. et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022; 387: 1547-1556
4 Pilonis ND, Bugajski M, Wieszczy P. et al. Participation in competing strategies for colorectal cancer screening: a randomized health services study (PICCOLINO Study). Gastroenterology 2021; 160: 1097-1105
5 Chung DC, Gray DM 2nd DM, Singh H. et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med 2024; 390: 973-983
6 Imperiale TF, Porter K, Zella J. et al. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med 2024; 390: 984-993